Platelet Rich Plasma Market Analysis by Application and End-use

The global platelet rich plasma market size was estimated at USD 476.1 million in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 12.0% from 2021 to 2028.

The global Platelet Rich Plasma Market size is estimated to reach USD 1.2 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 12.0% from 2021 to 2028. Several research studies have been performed recently to assess the conditions and incidences of platelet rich plasma (PRP) usage across both nonoperative as well as operative settings. Recent research on these lines has concluded that the breadth and use of platelet rich plasma have increased significantly among Medicare beneficiaries, which is expected to drive the market.

Technological advancements in the development of novel and innovative platelet rich plasma products are expected to propel market growth. Market participants are developing advanced products to reinforce their market share and overcome current limitations. In February 2020, Florida-based EmCyte Corporation received FDA’s 510(k) approval for its PurePRP Supraphysiologic Concentrating System, intended for producing platelet rich plasma from a small quantity of blood sample at Point-of-care (PoC) settings. This is an advanced autologous biologic concentrating system that can enable clinicians to improve their work.

The potential value of the market products lies in its ability to include high concentrations of platelet-derived fibrin and growth factors. Several research studies have demonstrated beneficial results with the usage of PRP in a wide range of clinical applications, such as orthopedics, sports medicine, cosmetic surgery, general surgery, neurosurgery, ophthalmic surgery, and others.

PRP injections are widely accepted in the orthopedic treatment, particularly focused towards joint pain relief and other bone defects, propelling the industry growth. It is also used to stimulate the formation of bone in spinal fusion surgeries. Additionally, integration of PRP in the management of COVID-19 patients, as an adjunct therapy is further expected to offer profitable business opportunities for the entities operational in this market.

Request a free sample copy or view report summary: Platelet Rich Plasma Market Report

Platelet Rich Plasma Market Report Highlights

• The pure PRP segment accounted for the largest revenue share of over 52.0% in 2020. Compared to Leukocyte Rich Platelet rich plasma (LR-PRP), pure PRP can promote better repair of bone defects
• LR-PRP can enhance bone regeneration by improving viability, proliferation, migration of cells in vitro, and osteogenesis and angiogenesis in vitro and in vivo
• However, LR-PRP products can produce adverse or inferior effects, making pure type more suitable for bone regeneration
• The combined use of P-PRP with �™-tricalcium phosphate (�™-TCP) is considered a simple, safe, and effective option in the treatment of bone defects. These factors are expected to boost the utilization of the same
• Orthopedics dominated the market in 2020 accounting for a market share of more than 29.0%, while dermatology is expected to witness the fastest growth rate over the forecast period
• A large number of orthopedic and general surgeries being performed in hospitals is contributing to the dominant share held by hospitals in the market
• The growing competition in the global market can be attributed to the presence of several well-established companies as well as small and midsized entities
• Established manufacturers are observing strategic product developments to ensure maximum product reach
• In October 2019, a new design for packaging was introduced by Croma-Pharma GmbH for the company’s ACP double syringe system. The unique appearance of Croma products has been integrated in this new design. Croma is an exclusive distributor of the Arthrex ACP double syringe system in 9 countries in Europe